RF01 | PMON43 Melanocortin-4 Receptor Agonism Enhances Sexual Brain Processing in Women with Hypoactive Sexual Desire Disorder

The source lists no authors.

Journal of the Endocrine Society1 Nov 2022

PMCIDPMC9625176PepBankPUB-96447859

Read at source Source pageAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In premenopausal women with HSDD, bremelanotide significantly increased self-reported sexual desire for up to 24 hours versus placebo.
In plain wordsIn women with low sexual desire, bremelanotide raised self-reported desire for up to 24 hours more than placebo.
Peptide
Bremelanotide (PT-141)
Outcome
IncreaseSelf-reported sexual desire up to 24 hours
Study
n = 31
Comparator
Placebo
Outcome group
Sexual function · Reproductive and sexual health
Studied dose
1.75 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
MC4R agonism significantly increased self-reported sexual desire for up to 24-hours post administration, compared to placebo (P=0.007).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a randomized, double-blinded, placebo-controlled, crossover clinical study, using psychometric, functional neuroimaging and hormonal analyses, to assess the effects of MC4R agonism on sexual brain processing in 31 premenopausal women with HSDD.
Summary · context
Participants attended on two occasions, receiving either a subcutaneous injection of an MC4R agonist (Bremelanotide 1.75 mg), or placebo, at each study visit, thereby acting as their own controls.
Report a problemFND-9644785901
02HumanRandomized controlled trialMechanism
In women with HSDD, bremelanotide enhanced cerebellar activity in response to visual erotic videos versus placebo.
In plain wordsIn women with low sexual desire, bremelanotide increased brain activity in the cerebellum while watching erotic videos, compared with placebo.
Peptide
Bremelanotide (PT-141)
Outcome
IncreaseCerebellar activity during erotic videos
Study
n = 31
Comparator
Placebo
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
1.75 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
During functional neuroimaging, MC4R agonism enhanced cerebellar and supplementary motor area activity, as well as deactivating the secondary somatosensory cortex, specifically in response to visual erotic videos, compared to placebo (Z=2.3, P<0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
specifically in response to visual erotic videos, compared to placebo (Z=2.3, P<0.05).
Summary · context
We conducted a randomized, double-blinded, placebo-controlled, crossover clinical study, using psychometric, functional neuroimaging and hormonal analyses, to assess the effects of MC4R agonism on sexual brain processing in 31 premenopausal women with HSDD.
Summary · context
Participants attended on two occasions, receiving either a subcutaneous injection of an MC4R agonist (Bremelanotide 1.75 mg), or placebo, at each study visit, thereby acting as their own controls.
Report a problemFND-9644785902
03HumanRandomized controlled trialMechanism
In women with HSDD, bremelanotide enhanced supplementary motor area activity in response to visual erotic videos versus placebo.
In plain wordsIn women with low sexual desire, bremelanotide increased activity in a movement-planning brain area while watching erotic videos, compared with placebo.
Peptide
Bremelanotide (PT-141)
Outcome
IncreaseSupplementary motor area activity during erotic videos
Study
n = 31
Comparator
Placebo
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
1.75 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
During functional neuroimaging, MC4R agonism enhanced cerebellar and supplementary motor area activity, as well as deactivating the secondary somatosensory cortex, specifically in response to visual erotic videos, compared to placebo (Z=2.3, P<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a randomized, double-blinded, placebo-controlled, crossover clinical study, using psychometric, functional neuroimaging and hormonal analyses, to assess the effects of MC4R agonism on sexual brain processing in 31 premenopausal women with HSDD.
Summary · context
Participants attended on two occasions, receiving either a subcutaneous injection of an MC4R agonist (Bremelanotide 1.75 mg), or placebo, at each study visit, thereby acting as their own controls.
Report a problemFND-9644785903
04HumanRandomized controlled trialMechanism
In women with HSDD, bremelanotide deactivated the secondary somatosensory cortex in response to visual erotic videos versus placebo.
In plain wordsIn women with low sexual desire, bremelanotide reduced activity in a body-sensation brain area while watching erotic videos, compared with placebo.
Peptide
Bremelanotide (PT-141)
Outcome
DecreaseSecondary somatosensory cortex activity during erotic videos
Study
n = 31
Comparator
Placebo
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
1.75 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
During functional neuroimaging, MC4R agonism enhanced cerebellar and supplementary motor area activity, as well as deactivating the secondary somatosensory cortex, specifically in response to visual erotic videos, compared to placebo (Z=2.3, P<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a randomized, double-blinded, placebo-controlled, crossover clinical study, using psychometric, functional neuroimaging and hormonal analyses, to assess the effects of MC4R agonism on sexual brain processing in 31 premenopausal women with HSDD.
Summary · context
Participants attended on two occasions, receiving either a subcutaneous injection of an MC4R agonist (Bremelanotide 1.75 mg), or placebo, at each study visit, thereby acting as their own controls.
Report a problemFND-9644785904
05HumanRandomized controlled trialMechanism
In women with HSDD, bremelanotide enhanced amygdala-insula functional connectivity during prolonged visual erotic stimuli versus placebo.
In plain wordsIn women with low sexual desire, bremelanotide strengthened communication between two brain areas during erotic stimuli, compared with placebo.
Peptide
Bremelanotide (PT-141)
Outcome
IncreaseAmygdala-insula functional connectivity
Study
n = 31
Comparator
Placebo
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
1.75 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
In addition, MC4R agonism enhanced functional connectivity between the amygdala-insula and amygdala-thalamus during prolonged visual erotic stimuli, compared to placebo (P=0.025).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a randomized, double-blinded, placebo-controlled, crossover clinical study, using psychometric, functional neuroimaging and hormonal analyses, to assess the effects of MC4R agonism on sexual brain processing in 31 premenopausal women with HSDD.
Summary · context
Participants attended on two occasions, receiving either a subcutaneous injection of an MC4R agonist (Bremelanotide 1.75 mg), or placebo, at each study visit, thereby acting as their own controls.
Report a problemFND-9644785905
06HumanRandomized controlled trialMechanism
In women with HSDD, bremelanotide enhanced amygdala-thalamus functional connectivity during prolonged visual erotic stimuli versus placebo.
In plain wordsIn women with low sexual desire, bremelanotide strengthened communication between two brain areas during erotic stimuli, compared with placebo.
Peptide
Bremelanotide (PT-141)
Outcome
IncreaseAmygdala-thalamus functional connectivity
Study
n = 31
Comparator
Placebo
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
1.75 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
In addition, MC4R agonism enhanced functional connectivity between the amygdala-insula and amygdala-thalamus during prolonged visual erotic stimuli, compared to placebo (P=0.025).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a randomized, double-blinded, placebo-controlled, crossover clinical study, using psychometric, functional neuroimaging and hormonal analyses, to assess the effects of MC4R agonism on sexual brain processing in 31 premenopausal women with HSDD.
Summary · context
Participants attended on two occasions, receiving either a subcutaneous injection of an MC4R agonist (Bremelanotide 1.75 mg), or placebo, at each study visit, thereby acting as their own controls.
Report a problemFND-9644785906
07HumanRandomized controlled trialEfficacy outcome
In women with HSDD, bremelanotide increased mean LH over the 300-minute study period.
In plain wordsIn women with low sexual desire, bremelanotide raised levels of the hormone LH over 300 minutes.
Peptide
Bremelanotide (PT-141)
Outcome
IncreaseLuteinizing hormone (LH)
Study
n = 31
Comparator
Placebo
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1.75 mg · subcutaneousAs given in this study (human).
Measurements
Mean increase in LH
1.1 iU/L
300-minute study
Source sentences
Summary
MC4R agonism resulted in a mean increase in LH of 1.1 iU/L (F [1,58] = 13.38, P=0.0005)
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a randomized, double-blinded, placebo-controlled, crossover clinical study, using psychometric, functional neuroimaging and hormonal analyses, to assess the effects of MC4R agonism on sexual brain processing in 31 premenopausal women with HSDD.
Summary · context
Participants attended on two occasions, receiving either a subcutaneous injection of an MC4R agonist (Bremelanotide 1.75 mg), or placebo, at each study visit, thereby acting as their own controls.
Report a problemFND-9644785907
08HumanRandomized controlled trialEfficacy outcome
In women with HSDD, bremelanotide increased mean FSH over the 300-minute study period.
In plain wordsIn women with low sexual desire, bremelanotide raised levels of the hormone FSH over 300 minutes.
Peptide
Bremelanotide (PT-141)
Outcome
IncreaseFollicle-stimulating hormone (FSH)
Study
n = 31
Comparator
Placebo
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1.75 mg · subcutaneousAs given in this study (human).
Measurements
Mean increase in FSH
0.35 iU/L
300-minute study
Source sentences
Summary
FSH of 0.35 iU/L (F [1,60] = 10.97, P=0.0016) across the 300-minute duration of the study
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a randomized, double-blinded, placebo-controlled, crossover clinical study, using psychometric, functional neuroimaging and hormonal analyses, to assess the effects of MC4R agonism on sexual brain processing in 31 premenopausal women with HSDD.
Summary · context
Participants attended on two occasions, receiving either a subcutaneous injection of an MC4R agonist (Bremelanotide 1.75 mg), or placebo, at each study visit, thereby acting as their own controls.
Report a problemFND-9644785908
09HumanRandomized controlled trialEfficacy outcome
In women with HSDD, bremelanotide had no effect on circulating estradiol.
In plain wordsIn women with low sexual desire, bremelanotide did not change estradiol levels.
Peptide
Bremelanotide (PT-141)
Outcome
No significant changeCirculating estradiol
Study
n = 31
Comparator
Placebo
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1.75 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
with no effect observed on circulating estradiol or progesterone levels.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a randomized, double-blinded, placebo-controlled, crossover clinical study, using psychometric, functional neuroimaging and hormonal analyses, to assess the effects of MC4R agonism on sexual brain processing in 31 premenopausal women with HSDD.
Summary · context
Participants attended on two occasions, receiving either a subcutaneous injection of an MC4R agonist (Bremelanotide 1.75 mg), or placebo, at each study visit, thereby acting as their own controls.
Report a problemFND-9644785909
10HumanRandomized controlled trialEfficacy outcome
In women with HSDD, bremelanotide had no effect on circulating progesterone.
In plain wordsIn women with low sexual desire, bremelanotide did not change progesterone levels.
Peptide
Bremelanotide (PT-141)
Outcome
No significant changeCirculating progesterone
Study
n = 31
Comparator
Placebo
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1.75 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
with no effect observed on circulating estradiol or progesterone levels.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a randomized, double-blinded, placebo-controlled, crossover clinical study, using psychometric, functional neuroimaging and hormonal analyses, to assess the effects of MC4R agonism on sexual brain processing in 31 premenopausal women with HSDD.
Summary · context
Participants attended on two occasions, receiving either a subcutaneous injection of an MC4R agonist (Bremelanotide 1.75 mg), or placebo, at each study visit, thereby acting as their own controls.
Report a problemFND-9644785910

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Abstract

PepBank is a research reference. Talk to a doctor before you use any peptide.